May 2022

Parkinson trial and internationalization

NEON trial in Parkinson’s patients: Dose escalation completed – Amendment approved to continue treatment for patients …

Read more

March 2022

Stéfan Halbherr and InnoMedica receive CLINAM Award

CLINAM Award 2022 for special achievements in nanomedicine for Stéfan Halbherr and InnoMedica The Scientific Committee of …

Read more

March 2022

Update Neurology Application and Capital Increase 2022

First Parkinson’s patients in the NEON study treated  On December 14, 2021, the clinical trial (NEON …

Read more

May 2021

Clinical trial application for Parkinson's disease treatment submitted

InnoMedica has reached an important milestone with the submission of the first Clinical Trial Application to …

Read more

March 2021

ODD for the application against ALS and capital increase 2021

Both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) approved InnoMedica’s …

Read more

February 2021


InnoMedica is close to submission of the marketing authorization application for its chemotherapy and plans to …

Read more

December 2020

December-Update 2020

In 2020, the InnoMedica team, now counting 39 employees, was able to reach important milestones. The …

Read more

October 2020


As a result of the successful financing round of CHF 10 million in April 2020, the …

Read more

March 2020

InnoMedica launches project for corona vaccination

The corona pandemic is a major challenge for everyone. In this context, InnoMedica plans to contribute …

Read more

June 2019

Annual general meeting 2019

The Board of InnoMedica invites all shareholders to attend the Annual General Meeting 2019. The Annual General Meeting …

Read more